Programmed Cell Death in Heart Failure: Mechanisms, Impacts, and Therapeutic Prospects
Dongda Wu1, Donghong Deng2, Biao Tang1,2
1Medical School, Hunan University of Chinese Medicine, 410208 Changsha, Hunan, China.
Reviews in Cardiovascular Medicine
|August 8, 2025
Summary
Programmed cell death (PCD) pathways are critical in heart failure. Targeting specific PCD mechanisms, like necroptosis and inflammation, shows promise for novel heart failure therapies.
Area of Science:
- Cardiology
- Cell Biology
- Pathophysiology
Background:
- Heart failure involves complex cellular death mechanisms.
- Programmed cell death (PCD) is a key factor in cardiac dysfunction.
- Understanding PCD is vital for treating heart failure.
Purpose of the Study:
- To review different forms of PCD in heart failure.
- To examine PCD mechanisms and therapeutic targets.
- To discuss novel therapeutic strategies for cardiac failure.
Main Methods:
- Literature review of recent research findings.
- Analysis of programmed cell death pathways (apoptosis, autophagy, necroptosis, pyroptosis, ferroptosis).
- Examination of therapeutic interventions targeting cell death and inflammation.
Main Results:
- PCD significantly contributes to heart failure progression.
- Inhibiting receptor-interacting protein kinases (RIPK1 and RIPK3) reduces cardiac injury.
- Targeting IL-1β may reduce both cell death and inflammation.
Conclusions:
- Programmed cell death is a pivotal factor in heart failure.
- Targeting specific PCD pathways offers promising therapeutic avenues.
- Novel strategies combining cell death and inflammation inhibition can improve heart failure management.
More Related Videos
Related Concept Videos
01:17Pathophysiology of Heart Failure
1.8K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.8K
01:29Heart Failure II: Pathophysiology
41
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
41
01:30Cardiomyopathy II: Dilated Cardiomyopathy
22
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
22
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
509
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
509
01:30Overview of Cell Death
7.7K
Cell death is an essential process where the body gets rid of old or damaged cells. Cell proliferation and death need to be balanced, as an imbalance between the two may lead to cancer or autoimmune diseases.
Cell death was observed in the early 19th century, but there was no experimental evidence to prove it. In 1842, Carl Vogt first discovered cell death in a metamorphic toad; however, it was not termed ‘cell death.’ Scientists discovered different cell death pathways only in the...
Cell death was observed in the early 19th century, but there was no experimental evidence to prove it. In 1842, Carl Vogt first discovered cell death in a metamorphic toad; however, it was not termed ‘cell death.’ Scientists discovered different cell death pathways only in the...
7.7K
01:26Heart Failure Drugs: Inotropic Agents
724
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
724